Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pricing of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback